Regulatory status, stated first: semaglutide is a prescription medicine. Obtaining it without a prescription, or through channels that are not authorised, is illegal in Ireland. Everything below concerns how research documentation is read and assessed — it is not guidance on obtaining any product.
The prescription medicine dispensed by a pharmacy for an approved indication, under medical supervision, and research-grade semaglutide sold as a peptide for laboratory and research use are not interchangeable — even though the label on both says the same word. Treating them as the same product because the name matches is where most of the confusion we hear starts. It's an understandable mix-up — the name is identical, the pharmacology it's built on is genuinely related, and most marketing copy has no incentive to draw the line clearly. But the confusion has real costs: a Dublin researcher who orders on the assumption that "semaglutide" alone guarantees what they're getting has skipped the one step that actually matters.
Before the detail: everything below concerns research and laboratory contexts only. Research-grade semaglutide as discussed on this page is not intended for human consumption, and nothing here is medical advice or a substitute for speaking to a doctor or pharmacist.
What semaglutide is, before the comparison
Semaglutide is a GLP-1 receptor agonist — a peptide engineered to mimic and extend the activity of a hormone the body already produces, which is what makes it the subject of such wide research and clinical interest in the first place. That underlying molecule is the same target compound whichever track it travels through: what differs isn't the molecule's identity, it's everything built around it — manufacturing standard, oversight, documentation, and legal status. Confusing "same named molecule" with "same product" is precisely the mistake this file exists to head off.
Getting that grounding right matters before any comparison, because the two tracks genuinely do diverge from there in every practical way that affects a buyer — which is exactly what the table below sets out to show, dimension by dimension.
It also matters for one very specific reason that comes up when reading a Certificate of Analysis. Semaglutide's structure includes a fatty-acid side chain, which is part of what extends the molecule's activity and is precisely why it needs a genuine LC-MS identity check rather than purity alone. A structurally similar analogue — a close but not identical peptide — could produce a respectable purity figure by HPLC while still being the wrong molecule entirely. Identity confirmation isn't a formality for this compound; it's the test doing most of the real work.
The compound, side by side
Here is the distinction the way we'd explain it to a researcher standing in front of two listings that both say "semaglutide."
| What to check | Prescription medicine (pharmacy) | Research-grade semaglutide |
|---|---|---|
| What it is | A finished injectable medicine, manufactured under pharmaceutical GMP and dispensed as a complete, labelled product. | A peptide supplied for laboratory and research use — not formulated, packaged or dispensed as a medicine. |
| Regulatory status | Holds a marketing authorisation for specific approved indications, granted through a formal licensing process. | Carries no marketing authorisation anywhere; sold and bought strictly as a research chemical. |
| How it reaches you | Pharmacy, against a prescription, with a pharmacist involved at the point of dispensing. | Direct order from a research-peptide supplier, with no pharmacist or prescriber in the chain. |
| Documentation that matters | Patient information leaflet and pharmacy dispensing record, both standardised by the licensing process. | An independent Certificate of Analysis for the specific batch — HPLC purity plus LC-MS identity confirmation. |
| Testing track record | Established once, through the licensing process itself — not something the patient re-verifies. | Varies by supplier and by batch; the buyer has to verify it themselves, every time, via the COA. |
| Intended context | A defined approved use, under a doctor's ongoing care. | Laboratory and research settings only. |
Illustrative comparison — not a claim about any specific product or supplier.
One thing the table intentionally leaves out: how much of anything to use, or how. This file describes what each product is and how to evaluate its paperwork, not how a compound is administered in either context. That question belongs with a doctor for the prescription medicine, and it isn't a question this research-literacy file answers for the other column either.
What documentation matters
In a research-context purchase, the prescription-side paperwork simply doesn't apply — there's no leaflet, no dispensing pharmacist, no equivalent step anywhere in the chain. That's exactly why an independent Certificate of Analysis carries the weight that leaflet and pharmacist would carry in the other column: it's the only check standing between you and an unverified vial.
A COA worth trusting is lot-specific, issued by a laboratory independent of the seller, and states both purity by HPLC and identity by LC-MS — the second test confirming the molecule tested actually matches the expected molecular weight of semaglutide's sequence, not merely that something in the vial is reasonably pure. A mismatch on identity means a different molecule entirely, not an "off-brand" version of the same one. Our editorial methodology sets out the full five-criteria standard behind that judgement, including how we treat a lot number that doesn't match the product label.
"Independent" is worth being precise about too: it means a laboratory with no financial relationship to the seller, not an in-house quality-control team the supplier happens to call a lab. A results sheet produced by the same company selling you the vial is a specification, not third-party verification, however professional it looks.
It's also worth expecting batch-to-batch variation as normal rather than surprising — which is exactly why per-batch testing matters as much as it does. A supplier who shows you a strong COA for one lot has told you nothing certain about the next one that ships. Each batch is its own claim, and each claim needs its own evidence.
Common confusions
The mix-ups we hear from Dublin researchers tend to repeat:
- Assuming a shared name means a shared formulation. It doesn't — the two are made, tested and distributed through entirely separate systems.
- Treating a listing's description as proof of content. A name on a label is a claim, not a test result; only a batch-specific COA is evidence.
- Reading a low price with vague documentation as a bargain. Cost gaps that large usually mean something was skipped — most often independent testing.
- Carrying pharmacy-context assumptions into a research purchase. Dosing supervision, ongoing monitoring, a pharmacist checking interactions — none of that infrastructure exists on the research side.
- Assuming "peptide" or "compounded" language implies pharmaceutical-grade oversight. Those are supply-chain descriptions, not quality guarantees.
- Assuming a supplier's international reputation substitutes for batch-specific paperwork. A well-known name in the research-peptide market is not the same evidence as a lab report tied to the lot in front of you.
Most of these share a root cause: borrowing the trust built into one system — licensed pharmacy medicine — and applying it to a completely separate one that has to earn that trust batch by batch, on its own paperwork.
Where that leaves Dublin researchers
In Ireland, as elsewhere, it's the authorisation process itself that separates a licensed medicine from everything else — a research listing never goes through it, and no seller's claim changes that. That's not a reason to avoid research-grade material; it's a reason to hold it to the documentation standard in the table above, rather than borrowing confidence from the name on the box next to it at the pharmacy.
The two tracks will likely keep sharing a name for as long as both exist — that's just how the research-peptide market has developed around approved compounds generally. What a Dublin buyer can control is which column of the table they're actually holding evidence for before they pay anyone.
This file sits alongside two others on this register, each built around its own structure: a dossier of five entries for BPC-157, and a research timeline for retatrutide — the newest compound on Dublin researchers' radar.
We keep the single source we've reviewed against our documentation standard behind one clearly marked page, separate from every guide on this register.
See the verified source